Connect Biopharma Holdings Ltd - 8-K Filing
Connect Biopharma reported Q1 2026 financial results with $46.0 million in cash as of March 31, 2026, a net loss of $19.4 million ($0.34 per share), and research and development expenses of $15.0 million driven by Phase 2 Seabreeze STAT studies for rademikibart. The company secured $20.2 million in gross proceeds from a private placement on March 31, 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $CNTB